KPRX — Kiora Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: Kiora Pharmaceuticals Receives Approval For Phase 2 Study Of Kio-101 For Treatment Of Ocular Presentation Of Autoimmune Diseases
Brief: Kiora Pharmaceuticals Files For Offering Of Up To 654,610 Shares - SEC Filing
Brief: Kiora Pharmaceuticals To Implement 1-For-40 Reverse Split
U.S. STOCKS ON THE MOVE-JD.Com, Tesla, Autodesk
Kiora Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Snap, Tesla, Schlumberger, social media stocks
Brief: Kiora Pharma Files For Offering 26.2 Mln Shares Of Common Stock
Kiora Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Kiora Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Kiora Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Kiora Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Inc - Effective As Of June 16, 2022, Drexler Resigned As Interim Chief Financial Officer Of Company
Kiora Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Kiora Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Inc Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Kiora Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Kiora Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Kiora Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Inc - On April 21, Appointed Susan L. Drexler As Interim Chief Financial Officer